Related Experiment Video
Updated: Jan 27, 2026
Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
Atrial fibrillation ablation in practice: assessing CABANA generalizability
Peter A Noseworthy1,2, Bernard J Gersh2, David M Kent3,4
1Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, 200 1st St SW, Rochester, MN, USA.
Insights
Catheter ablation for atrial fibrillation (AF) significantly reduced mortality, stroke, and bleeding compared to drug therapy in a large observational study. The benefits were most pronounced in patients eligible for the CABANA trial.
Area of Science:
- Cardiology
- Clinical Trials
- Health Services Research
Background:
- Atrial fibrillation (AF) management involves balancing the risks and benefits of catheter ablation versus antiarrhythmic drug therapy.
- The Catheter Ablation vs. Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) trial provided key insights into this comparison.
- Assessing the generalizability of the CABANA trial findings to real-world clinical practice is crucial.
Purpose of the Study:
- To evaluate the effectiveness of catheter ablation compared to medical therapy for atrial fibrillation in a large, real-world patient cohort.
- To assess the impact of ablation on major adverse events, including mortality, stroke, bleeding, and cardiac arrest.
- To determine if the benefits of ablation observed in the CABANA trial are replicated in routine clinical care and to assess generalizability.
Main Methods:
- A parallel observational study using a large US administrative database.
- Inclusion of 183,760 patients with atrial fibrillation treated between August 2009 and April 2016.
- Propensity score weighting on 90 dimensions to balance patients receiving ablation (N=12,032) versus medical therapy (N=171,728).
Main Results:
- Catheter ablation was associated with a significant reduction in the composite endpoint of all-cause mortality, stroke, major bleeding, and cardiac arrest (HR 0.75, P < 0.001).
- The risk reduction was greatest among patients potentially eligible for the CABANA trial (HR 0.70, P < 0.001).
- A statistically significant reduction in the composite endpoint was also observed in patients meeting at least one trial exclusion criterion (HR 0.85, P = 0.01).
Conclusions:
- Catheter ablation for atrial fibrillation demonstrates significant benefits in reducing major adverse events in routine clinical practice.
- These findings support the generalizability of the CABANA trial's conclusions to a broader patient population.
- The study highlights the effectiveness of ablation, particularly in patients who meet trial eligibility criteria, but also shows benefits in those with exclusion criteria.
Aims:
The Catheter Ablation vs. Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) trial aimed to assess the impact of ablation on morbidity and mortality. This observational study was conducted in parallel to CABANA to assess trial generalizability.
Methods And Results:
Using a large US administrative database, we identified 183 760 patients with atrial fibrillation (AF) treated with ablation or medical therapy (antiarrhythmic or rate control drugs) between 1 August 2009 and 30 April 2016 (CABANA enrolment period). Propensity score weighting was used to balance patients treated with ablation (N = 12 032) or medical therapy alone (N = 171 728) on 90 dimensions. Ablation was associated with a reduction in the composite endpoint of all-cause mortality, stroke, major bleeding, and cardiac arrest [hazard ratio (HR) 0.75, 95% confidence interval (CI) 0.70-0.81; P < 0.001]. The majority of patients (73.8%) were potentially trial eligible; among whom the risk reduction associated with ablation was greatest (HR 0.70, 95% CI 0.63-0.77; P < 0.001). Among the 3.8% of patients who failed to meet the inclusion criterion, i.e. patients under 65 years without stroke risk factors, the event rates were low and there was no significant relationship with ablation (HR 0.67, 95% CI 0.29-1.56; P = 0.35). Among the 22.4% patients who met at least one of the trial exclusion criteria, there was a lesser but statistically significant reduction associated with ablation (HR 0.85, 95% CI 0.75-0.95; P = 0.01).
Conclusion:
In routine clinical care, ablation was associated with a reduction in the primary CABANA composite endpoint of all-cause mortality, stroke, major bleeding, and cardiac arrest, particularly in patients who were eligible for the trial.
More Related Videos
06:25Cooling or Warming the Esophagus to Reduce Esophageal Injury During Left Atrial Ablation in the Treatment of Atrial Fibrillation
Published on: March 15, 2020
04:58Reduced Procedure Time and Variability with Active Esophageal Cooling During Radiofrequency Ablation for Atrial Fibrillation
Published on: August 25, 2022
Related Concept Videos
03:03Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
03:03Amyloid Fibrils
01:11Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
01:16Characteristics of Practical Op Amps
The ratio of differential gain to the common-mode gain is defined as the common-mode rejection ratio (CMRR). This ratio quantifies the ability of operational amplifiers (op-amps) to reject common-mode...
01:30Theoretical Foundations of Nursing Practice
Theories provide a perspective to assess patients' conditions and organize data and methods. They also assist in analyzing and interpreting information. They represent a...
01:28Equivalent Circuits for Practical Transformers
In a practical transformer, each winding exhibits resistance and leakage reactance. The...